HTRA3-high patients with GC had worse histological types (diffuse type), lower tumor differentiation, later clinicopathological stages (especially greater primary tumor growth), and were less prone to have TP53 mutations, highlighting the potential role of HTRA3 in the development of GC. The gene discussed is HTRA3; the disease is gastric cancer.